CLINICAL APPLICATION & CRITERIA
Immunotherapy & Checkpoint Inhibitors in China
Immunotherapy harnesses the body’s own immune system to recognize and destroy cancer cells. The most widely used class is immune checkpoint inhibitors — antibodies targeting PD-1, PD-L1, or CTLA-4 — that release natural brakes on T cells, enabling them to attack tumors. Unlike chemotherapy or targeted therapy, immunotherapy can produce durable, long-term remissions that persist years after treatment ends, even in advanced metastatic disease. Responses are enriched in patients whose tumors express predictive biomarkers such as PD-L1, high tumor mutational burden (TMB-H), or microsatellite instability (MSI-H/dMMR). Combination approaches with chemotherapy, targeted agents, or radiation continue to expand the受益 patient population.
- Durable Responses in Selected Patients
- Broad Tumor-Type Applications
- Biomarker-Guided Therapy
- Innovative Combinations
- Manageable Safety Profile
- Neoadjuvant & Adjuvant Use
CLINICAL CANCER INDICATIONS
Key Cancers Treated with Immunotherapy in China
World-leading first-in-class bispecific antibodies, high-affinity PD-1/PD-L1 inhibitors, and synergistic combination protocols across solid tumors:
WHY CHOOSE US
Why Choose China Cancer Help for Immunotherapy
A specialized cross-border continuum connecting international patients directly with China’s world-leading immuno-oncology ecosystem.
China has become a global powerhouse in immuno-oncology, with the world’s largest number of clinical trials for PD-1/PD-L1 inhibitors. Multiple domestically developed checkpoint antibodies — sintilimab (Innovent), tislelizumab (BeiGene), camrelizumab (Hengrui), toripalimab (Junshi), and penpulimab — have received NMPA approval, with several now recognized by the FDA and EMA. NRDL negotiations have driven anti-PD-1 prices down to roughly 10–20% of US list prices, making immunotherapy widely accessible to both domestic and international patients.
Chinese companies are pioneering novel bispecific antibodies — including ivonescimab, the world’s first approved PD-1×VEGF bispecific — which demonstrated a statistically significant overall survival benefit over standard PD-1 plus chemotherapy in squamous NSCLC, a result unmatched by any other anti-PD-(L)1 regimen. Fast-track NMPA approvals, a vast patient base for rapid clinical development, and extensive real-world data on high-incidence Chinese cancers (esophageal, gastric, liver, nasopharyngeal) make China a global leader in delivering cutting-edge immunotherapy.
CASE EVALUATION PATHWAY
A Structured Pathway from Records to Care
A transparent, four-stage continuum connecting preliminary clinical evaluation to official hospital acceptance, specialized inpatient care, and ongoing continuity.
01. Submit Records Online
02. Pre-Screen & Doctor Match
03. Doctor Consultation
04. Travel to China & Care
PATIENT FAQS
Frequently Asked Questions
Key clinical, financial, and logistical insights for international Immune Checkpoint Inhibitors (ICI) patients considering care in China.
IMMUNOTHERAPY PRE-ASSESSMENT
Request a Confidential Case Review for Immunotherapy & Checkpoint Inhibitors
Submit your contact details, confirmed diagnosis, and main question below. You do not need to upload any medical files at this stage. Our clinical coordinator will contact you directly within 24–48 hours to discuss potential immunotherapy and checkpoint inhibitor pathways in China and assist you in gathering the specific medical records needed for expert hospital review.